Paper 100 Entered: September 26, 2017

## UNITED STATES PATENT AND TRADEMARK OFFICE

\_\_\_\_\_

### BEFORE THE PATENT TRIAL AND APPEAL BOARD

MYLAN LABORATORIES LIMITED, Petitioner

v.

AVENTIS PHARMA S.A., Patent Owner.

Case IPR2016-00712 Patent 8,927,592 B2

Before BRIAN P. MURPHY, TINA E. HULSE, and CHRISTOPHER M. KAISER, *Administrative Patent Judges*.

MURPHY, Administrative Patent Judge.

DECISION
On Motions to Seal
37 C.F.R. §§ 42.14



On February 10, 2017, we granted Patent Owner's Motion to Seal Exhibits 2149 (portions of ¶ 29), 2170, 2171, 2176 (portions of ¶¶ 47, 164), 2179, 2182, and 2211. Paper 35. We stated that Patent Owner has demonstrated good cause for keeping the identified information under seal, because it relates to highly sensitive and confidential business information of Patent Owner that could cause competitive harm to Patent Owner. *Id.* at 3. Patent Owner has filed public versions of Exhibits 2149 (Tate Declaration) and 2176 (Sartor Declaration) with appropriately limited redactions (Ex. 2149 ¶ 29; Ex. 2176 ¶¶ 47, 164), so as to provide the thrust of Patent Owner's argument without compromising the underlying confidential business information.

We ordered Patent Owner to file the Stipulated Protective Order to which the parties had agreed. Paper 35, 3. Patent Owner filed the so-ordered Stipulated Protective Order on February 15, 2017. Paper 36.

The parties subsequently filed a series of papers and exhibits under seal, with accompanying motions to seal and redacted public versions, in accordance with the terms of the Stipulated Protective Order. The motions are uncontested except for one motion to seal, addressed separately below.

The following chart summarizes the motions to seal and the confidential papers and exhibits that are the subject of the motions.

Motion to Seal Paper	Description	Papers and Exhibits
Number		Subject to Sealing
45	Petitioner's Motion to	Paper 43 (MTA Opp.)
	Seal Opposition to	Ex. 1042 (Tate Depo.
	Contingent Motion to	Tr.)
	Amend ("MTA")	Ex. 1043 (Seth Reply
		Dec.),
		Ex. 1044 (McSorley
		Dec.),
		Ex. 1054,
		Ex. 1065,



## IPR2016-00712 Patent 8,927,592 B2

		E 1000 1070
		Exs. 1069–1072,
		Ex. 1074,
		Ex. 1079, and
		Exs. 1089–1090
54	Patent Owner's Motion	Paper 53 (MTA Reply)
	to Seal MTA Reply and	Ex. 2258 (Seth Depo.
	Ex. 2258	Tr. April 14, 2017
		(referencing sealed Ex.
		2182))
56	Patent Owner's Motion	Ex. 2211 (FDA Meeting
	to Seal Ex. 2211	Minutes of June 28,
		2006 meeting with
		Sanofi-Aventis)
62	Patent Owner's Motion	Ex. 2261 (McSorley
	to Seal Ex. 2261	Depo. Tr. April 19,
		2017)
65	Petitioner's Motion to	Paper 64 (referencing
	Seal Petitioner's Motion	Ex. 1042 (Tate Depo.
	to Exclude Evidence	Tr.) and Ex. 2261
		(McSorley Depo. Tr.))
74	Patent Owner's Motion	Paper 72 (referencing
	to Seal Patent Owner's	Exs. 1042 (Tate Depo.
	Opp. to Petitioner's	Tr.), 2149, 2170–2171,
	Motion to Exclude.	2179, and 2261
		(McSorely Depo. Tr.))
76	Petitioner's Motion to	Paper 77 (referencing
	Seal Petitioner's Opp.	Ex. 1042 (Tate Depo.)
	To Patent Owner's Mot.	and Ex. 1044
	To Exclude Exs. 1089	(McSorley Dec.))
	and 1090	
83	Patent Owner's Motion	Paper 81 (referencing
	to Seal Patent Owner's	Ex. 1044 (McSorley
	Observations on Cross-	Dec.) and Ex. 2261
	Examination of Robert	(McSorley Depo. Tr.))
	McSorley	
88	Petitioner's Motion to	Paper 89 (referencing
	Seal Reply in Support	Ex. 1042 (Tate Depo.
	of Motion to Exclude	Tr.) and Papers 64 and
	Evidence	72)
	Evidence	12)



## IPR2016-00712 Patent 8,927,592 B2

91	Petitioner's Motion to	Paper 92 (referencing
	Seal Petitioner's	Ex. 1044 (McSorley
	Response to Patent	Dec.), Ex. 1065, Ex.
	Owner's Observations	1068, Ex. 1071, and Ex.
	on Cross-Examination	2261 (McSorley Depo.
	of Robert McSorely	Tr.))
97	Patent Owner's Brief in	
	Support of Petitioner's	
	Motion to Seal Patent	
	Owner's Confidential	
	Information (Paper Nos.	
	45, 65, 76, 88, 91)	

The record for an *inter partes* review shall be made available to the public, except as otherwise ordered, and a document filed with a motion to seal shall be treated as sealed until the motion is decided. 35 U.S.C. § 316(a)(1); 37 C.F.R. § 42.14. The standard for granting a motion to seal is "good cause." 37 C.F.R. § 42.54. There is a strong public policy that favors making information filed in *inter partes* review proceedings open to the public. *See Garmin Int'l v. Cuozzo Speed Techs., LLC*, Case IPR2012-00001, slip op. at 1–2 (PTAB Mar. 14, 2013) (Paper 34) (discussing Board standards applied to motions to seal). The moving party bears the burden of showing that the relief requested should be granted. 37 C.F.R. § 42.20(c).

Satisfaction of the burden requires a showing that the information is truly confidential, and that such confidentiality outweighs the strong public interest in having an open record. *See Garmin* at 3. In the instant case, Patent Owner asserts that, if made public, the aforementioned highly sensitive business information could cause competitive harm to Patent Owner. Paper 97, 5.



### A. Uncontested Motions to Seal

On March 14, 2017, Petitioner moved to seal its Opposition to Patent Owner's Contingent Motion to Amend (Paper 43) and the Reply Declaration of Dr. Rahul Seth (Exhibit 1043) because the documents discuss sealed Exhibit 2182. Paper 45 at 3-4. Petitioner moved to seal Exhibit 1054 because it was produced and designated by Patent Owner as confidential and relates to FDA meeting minutes that were previously sealed (Exhibit 2211). *Id.* at 5. Petitioner also moved to seal the transcript of the deposition of Mr. Michael E. Tate (Exhibit 1042), whose previous declaration was sealed (Exhibit 2149), because the transcript discusses Patent Owner's confidential business information. *Id.* at 4. Petitioner moved to seal Exhibits 1065, 1068-1072, 1074, and 1079 because they were produced and designated confidential by Patent Owner and are of "substantially similar character" to previously sealed Exhibits 2170 and 2179. See id. at 2, 5. Accordingly, Petitioner also moved to seal the Declaration of Mr. Robert McSorley (Exhibit 1044) because it discusses "highly sensitive business information" of Patent Owner in Exhibits 1065, 1068-1072, 1074, and 1079. See id. at 2, 4–5.

On May 2, 2017, Patent Owner filed a motion to seal the transcript of the deposition of Mr. McSorley (Exhibit 2261) because, *inter alia*, the transcript discusses Patent Owner's confidential business information from internal marketing documents. Paper 62, 2–3. Also on May 2, 2017, Petitioner filed a motion to seal its Motion to Exclude Evidence (Paper 64) because the motion discusses the deposition transcripts of Mr. Tate and Mr. McSorley, both of which have been designated confidential and are the subject of motions to seal. Paper 65, 1. The parties subsequently exchanged redactions to the deposition transcripts of Mr. Tate and Mr. McSorley, with



# DOCKET

# Explore Litigation Insights



Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

# **Real-Time Litigation Alerts**



Keep your litigation team up-to-date with **real-time** alerts and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## **Advanced Docket Research**



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

# **Analytics At Your Fingertips**



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

### API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

#### **LAW FIRMS**

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

#### **FINANCIAL INSTITUTIONS**

Litigation and bankruptcy checks for companies and debtors.

## **E-DISCOVERY AND LEGAL VENDORS**

Sync your system to PACER to automate legal marketing.

